Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Fatty acid elongases (EC 22.214.171.124), such as ELOVL6, use malonyl-CoA as a 2-carbon donor in the first and rate-limiting step of fatty acid elongation (Moon et al., 2001. Additionally we are shipping and many more products for this protein.
Showing 10 out of 52 products:
Human Polyclonal ELOVL6 Primary Antibody for EIA, WB - ABIN452952
Lu, Dollé, Imholz, van t Slot, Verschuren, Wijmenga, Feskens, Boer: Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations. in Journal of lipid research 2008
Human Polyclonal ELOVL6 Primary Antibody for ELISA, WB - ABIN1451250
Hillier, Graves, Fulton, Fulton, Pepin, Minx, Wagner-McPherson, Layman, Wylie, Sekhon, Becker, Fewell, Delehaunty, Miner, Nash, Kremitzki, Oddy, Du, Sun, Bradshaw-Cordum, Ali, Carter, Cordes, Harris et al.: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. ... in Nature 2005
These findings suggest that Elovl6-mediated changes in hepatic FA composition, especially oleic acid (C18 (show BBS9 Antibodies):1n-9), control handling of hepatic cholesterol and BA, which protects against hepatotoxicity and steatohepatitis
Elongation of Very Long Chain fatty acids 6 (Elovl6) is necessary for the thermogenic action of brown adipose tissue
Data (including data from studies in knockout mice) confirm Elovl6 as only enzyme elongating palmitate to oleate; elongation of palmitoleate to vaccinate does not require Elovl6; deletion of Elovl6 does not prevent nonalcoholic fatty liver disease.
Our findings suggest that Elovl6 could be involved in insulin (show INS Antibodies) secretory capacity per beta-cell and diabetes.
Elovl6 deficiency results in a change in fatty acid composition, induction of apoptosis, TGF-beta1 expression and reactive oxygen species generation.
Elovl6 is a critical modulator for atherogenic high-fat diet-induced inflammation, oxidative stress, (show SAMSN1 Antibodies) and fibrosis in the liver.
REVIEW: fatty acid metabolism and lipotoxicity; discussion of the role of Elovl6 in newly recognized aspects of metabolic regulation
Elovl6 in macrophages may contribute to foam cell formation and progression of atherosclerosis.
data indicate this elongase is a lipogenic enzyme regulated by SREBP-1 (show SREBF1 Antibodies), playing an important role in de novo synthesis of long-chain saturated and monosaturated fatty acids in conjunction with fatty acid synthase (show FASN Antibodies) and stearoyl-CoA desaturase (show SCD Antibodies).
These data demonstrated that Elovl-6 is regulated directly and primarily by SREBP-1c (show SREBF1 Antibodies).
). In conclusion, we found an interaction between the HLA-Cw6 and LCE genotypes on disease improvement among psoriatic patients treated with anti-TNFs.
KAR (show HSD17B12 Antibodies) regulates ELOVL6 via two modes; KAR (show HSD17B12 Antibodies) may induce conformational changes in ELOVL6; conversion of 3-ketoacyl-CoA to 3-hydroxyacyl-CoA by KAR (show HSD17B12 Antibodies) may facilitate release of the product from the ELOVL6-KAR (show HSD17B12 Antibodies) complex.
human liver samples from patients with Non-alcoholic steatohepatitis or Non-alcoholic steatohepatitis-related hepatocellular carcinoma showed an elevated expression of the elongase ELOVL6, which is responsible for the elongation of C16 fatty acids.
The study indicated that the ELOVL6 gene polymorphism rs12504538 is associated with an increased risk of T2DM, because it causes an increase in insulin (show INS Antibodies) resistance.
Elovl6 expression is significantly downregulated in human lung with idiopathic pulmonary fibrosis.
Elovl6 expression is positively correlated with severity of hepatosteatosis and liver injury in NASH (show SAMSN1 Antibodies) patients.
study showed cystic fibrosis (show S100A8 Antibodies) cells exhibit increased metabolism along metabolic pathways leading to n-7 and n-9 fatty acids compared with wild-type cells; changes are accompanied by increased expression of Delta5, Delta6 and Delta9 desaturases and elongases 5 and 6
Genetic variations in the ELOVL6 gene were associated with insulin (show INS Antibodies) sensitivity in this population-based study.
Studies suggest that inhibition of ELOVL6 could be a new therapeutic approach for the treatment of insulin (show INS Antibodies) resistance, diabetes, cardiovascular disease, and other metabolic diseases.
ELOVL6:c.-394G > A polymorphism as the causal mutation for the QTL on pig chromosome 8 that affects fatty acid composition in pigs.
ELOVL6 as a potential causal gene for the QTL and for controlling the overall balance of fatty acid composition in pigs
Fatty acid elongases (EC 126.96.36.199), such as ELOVL6, use malonyl-CoA as a 2-carbon donor in the first and rate-limiting step of fatty acid elongation (Moon et al., 2001
3-keto acyl-CoA synthase elovl6
, ELOVL FA elongase 6
, ELOVL fatty acid elongase 6
, elongation of very long chain fatty acids protein 6
, long-chain fatty-acyl elongase
, very-long-chain 3-oxoacyl-CoA synthase 6
, 3-keto acyl-CoA synthase Elovl6
, fatty acyl-CoA elongase
, long chain fatty acid elongase
, long chain fatty acyl elongase
, myelin-associated SUR4 protein
, elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3
, 3-keto acyl-CoA synthase ELOVL6
, ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)
, fatty acid elongase 2
, ELOVL family member 6, elongation of long chain fatty acids
, elongation of very long chain fatty acids family member protein 6